Top

American Journal of Clinical Dermatology

Published in:

Open Access 01-11-2021 | Vulgar Psoriasis | Letter to the Editor

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study

Authors: Emma Borg, Henrik Thoning

Published in: American Journal of Clinical Dermatology | Issue 6/2021

Excerpt

To the Editor: …

Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–79.CrossRef

Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686–9.CrossRef

van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5.CrossRef

Title: Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study
Authors: Emma Borg
Henrik Thoning
Publication date: 01-11-2021
Publisher: Springer International Publishing
Keywords: Vulgar Psoriasis
IL-23 Inhibitor
Published in: American Journal of Clinical Dermatology / Issue 6/2021
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-021-00642-3

At a glance: The STEP trials

Springer Medicine

Comment on: Drug Survival of IL‑12/23, IL‑17 and IL‑23 Inhibitors for Psoriasis Treatment: A Retrospective Multi‑Country, Multicentric Cohort Study

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2021

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Sunscreens and Photoaging: A Review of Current Literature

DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020

Investigational Treatments for Epidermolysis Bullosa

The Pathogenesis and Management of Acne-Induced Post-inflammatory Hyperpigmentation

Acknowledgement to Referees